Sugi Predict

Sugi Predict / Compounds / SCHEMBL4276567

SCHEMBL4276567

SCHEMBL4276567

CCOC(=O)c1cc2ccnc(Cl)c2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 1/20 0.55
▸ CCNB1 P14635 1/20 0.55
▸ ALOX15 P16050 1/20 0.54
▸ RAB9A P51151 4/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MMP13 P45452 7/20 0.49
▸ MMP2 P08253 5/20 0.49
▸ MMP14 P50281 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29942182 1.00 CDK1 (0.55) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL30122360 0.99 CDK1 (0.54) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL20504460 0.85 XDH (0.47) GLAGAAMAPTALPL
SCHEMBL27335723 0.83 RAB9A (0.52) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL24403024 0.81 ALOX15 (0.53) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL30220587 0.81 KDM4E (0.47) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL25581554 0.80 RXFP1 (0.40) ALDH1A1HPGDHSD17B10LMNAMEN1
SCHEMBL26620078 0.78 CDK1 (0.52) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL30296805 0.78 CDK1 (0.52) CDK1CCNB1ALOX15RAB9AKDM4E
SCHEMBL4073035 0.78 HPGD (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103559-B1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2026-03-04 — — EP disclosed
EP-4370207-B1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-12-17 — — EP disclosed
US-20250353848-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION 2025-11-20 — — US disclosed
US-12473304-B2 Heterocyclic PAD4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-18 — — US disclosed
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF REGOR PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024255762-A1 CBL-B INHIBITOR 上海齐鲁制药研究中心有限公司 2024-12-19 — — WO disclosed
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2024-11-07 — — US disclosed
US-12012398-B2 Bicyclic compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2024-06-18 — — US disclosed
EP-4370207-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS Nido Biosciences, Inc. (US) 2024-05-22 — — EP disclosed
WO-2023230612-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 — — WO disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 — — US disclosed
WO-2023083365-A1 PAD4 INHIBITORS AND USE THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-05-19 — — WO disclosed
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2023-02-09 — — US disclosed
WO-2023287704-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. (US) 2023-01-19 — — WO disclosed
EP-4103559-A1 HETEROCYCLIC PAD4 INHIBITORS Bristol-Myers Squibb Company (US) 2022-12-21 — — EP disclosed
CN-115348961-A Heterocyclic PAD4 inhibitors 百时美施贵宝公司 2022-11-15 — — CN disclosed
WO-2021163254-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-19 — — WO disclosed
WO-2021163254-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-19 — — WO disclosed
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 — — US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 CDK1 839/4885CCNB1 2518/4885ALOX15 3079/4885
US-20250353848-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI1, PADI6 CDK1 1263/4885CCNB1 3193/4885ALOX15 3155/4885
US-12473304-B2 Heterocyclic PAD4 inhibitors PADI6, PADI4, PADI1 CDK1 749/4885CCNB1 2055/4885ALOX15 3598/4885
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF PADI4, PADI6, PADI2 CDK1 3938/4885CCNB1 4666/4885ALOX15 3314/4885
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 CDK1 839/4885CCNB1 2518/4885ALOX15 3079/4885
US-12012398-B2 Bicyclic compounds as androgen receptor modulators AR, FSHR, NCOA3 CDK1 902/4885CCNB1 2647/4885ALOX15 3037/4885
US-20080064715-A1 6-Azaindole Compound RELA, NFKBIA, GPR119 CDK1 366/4885CCNB1 1143/4885ALOX15 4279/4885
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI2, PADI6 CDK1 1623/4885CCNB1 3094/4885ALOX15 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.